Expertise in
7
conditions

Olivier J. Glehen

Pierre-la-treiche, FR 
Expertise in
7
conditions
Pierre-la-treiche, FR 

Overview

Olivier Glehen practices practicing medicine in Pierre-la-treiche, France.

Mr. Glehen is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Pseudomyxoma Peritonei, Ovarian Cancer, Mesothelioma, Hepato-Pancreato-Biliary Surgery, and Ileostomy.

He is actively involved in clinical research, co-authoring 366 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

Pierre-la-treiche, 69495, France
Other Locations
Lyon, France
Oullins, 69395, France
Auvergny, France
Aix Marseille Univ, APHM, CHU Timone
Marseille, France
Villeurbanne, France
Chemin-d'aisey, 69495, France
AP HP, CHU Henri Mondor
Creteil, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study.
GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study.
Enrollment Status: Completed
Publish Date: August 24, 2026
Intervention Type: Procedure, Drug
Study Drug: HIPEC with oxaliplatin
Study Phase: Phase 3
A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer
A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2026
Intervention Type: Procedure, Drug
Study Drug: Hyperthermic Intra-PEritoneal Chemotherapy
Study Phase: Phase 3
Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
Enrollment Status: Active_not_recruiting
Publish Date: March 16, 2026
Intervention Type: Drug
Study Drug: HIPEC
Study Phase: Phase 3
Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment : Phase II Multicentric Randomized Double Bland Placebo Controlled Study
Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment : Phase II Multicentric Randomized Double Bland Placebo Controlled Study
Enrollment Status: Completed
Publish Date: December 19, 2025
Intervention Type: Drug
Study Drug: Pasireotide
Study Phase: Phase 2
Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies
Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies
Enrollment Status: Completed
Publish Date: December 19, 2025
Intervention Type: Other
Study Phase: Not Applicable
View 4 Less Clinical Trials

366 Total Publications

Sarcopenia and outcomes after CRS ± HIPEC for gastric peritoneal metastases: no association with major morbidity and poorer survival in synchronous disease.
Sarcopenia and outcomes after CRS ± HIPEC for gastric peritoneal metastases: no association with major morbidity and poorer survival in synchronous disease.
Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Published: July 07, 2026

Frequently Asked Questions about Olivier J. Glehen

Is Olivier J. Glehen a top-rated expert for Pseudomyxoma Peritonei?

MediFind is an objective health platform that identifies experts based on real-world data. Olivier J. Glehen is classified as an Elite expert for Pseudomyxoma Peritonei, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Olivier J. Glehen participate in research or clinical trials?

Yes. Olivier J. Glehen has published 366 articles and abstracts on conditions like Pseudomyxoma Peritonei. You can view a list of Olivier J. Glehen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Glehen's expertise for a condition
ConditionClose
    View All 37 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile